Complete Filing Data
OKYO Pharma Ltd reported Cash And Cash Equivalents of $4.60 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean OKYO Pharma Ltd did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Profit Loss | -$4.7M | -$16.8M | -$13.3M | -$5.4M | -$3.4M | -$1.5M |
| Research And Development Expense | $2.3M | $8.2M | $6.3M | $1.6M | $348.3K | $518.1K |
| Profit Loss Before Tax | -$8.0M | -$16.8M | -$13.3M | -$6.2M | -$3.4M | -$1.6M |
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation | -$159.0K | -$141.1K | -$441.0K | -$837.2K | $346.4K | $86.7K |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | -$159.0K | $141.1K | -$441.0K | -$837.2K | $346.4K | $86.7K |
| Operating Expense Excluding Cost Of Sales | $7.1M | $15.7M | $13.2M | $6.2M | $3.4M | $1.5M |
| Comprehensive Income | -$4.9M | -$16.7M | -$13.7M | -$6.3M | -$3.0M | -$1.5M |
| Income Tax Expense Benefit Continuing Operations | -$12.2K | -$786.5K | -$25.0K | -$76.3K | ||
| Adjustments For Reconcile Profit Loss | $2.0M | $199.2K | $78.5K | |||
| Adjustments For Income Tax Expense | -$3.3M | $22.4K | -$12.2K | -$786.5K | ||
| Impairment Of Loan | -$11.2K | -$132.7K | ||||
| Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss Loans And Advances | $11.2K | $132.7K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents | $4.6M | $826.8K | $4.0M | $2.7M | $6.9M | $235.5K | $627.6K | |
| Retained Earnings | -$143.0M | -$142.5M | -$125.7M | -$112.4M | -$106.0M | -$109.0M | ||
| Cash Flows From Used In Operating Activities | -$1.8M | -$9.5M | -$7.7M | -$5.5M | -$1.6M | -$1.2M | ||
| Cash Flows From Used In Financing Activities | $2.7M | $6.2M | $9.3M | $2.2M | $7.8M | $963.3K | ||
| Adjustments For Increase Decrease In Trade And Other Payables | $1.2M | $2.8M | $3.0M | -$298.0K | $886.1K | $271.2K | ||
| Adjustments For Increase Decrease In Related Party Payables | $500.6K | -$570.1K | $814.3K | $48.9K | -$46.3K | $38.0K | ||
| Adjustments For Decrease Increase In Trade And Other Receivables | -$90.4K | $440.3K | $167.7K | -$802.2K | $208.9K | -$122.2K | ||
| Cash Flows From Used In Investing Activities | -$1.2K | -$5.9K | -$1.7K | -$18.1K | -$132.7K | |||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $1.2K | $5.9K | $1.7K | $6.9K | ||||
| Trade And Other Current Payables | $8.4M | $7.1M | $4.3M | $1.3M | $1.7M | |||
| Property Plant And Equipment | $2.0K | $3.4K | $7.2K | $5.2K | $6.1K | |||
| Noncurrent Assets | $2.0K | $3.4K | $7.2K | $5.2K | $104.6K | |||
| Liabilities | $9.2M | $7.4M | $7.3M | $1.4M | $1.8M | |||
| Equity And Liabilities | $3.7M | $1.5M | $5.2M | $4.3M | $7.1M | |||
| Current Taxation Receivable | $1.9M | $559.1K | $559.1K | $781.7K | $26.3K | |||
| Current Liabilities | $9.2M | $7.4M | $7.3M | $1.4M | $1.7M | |||
| Current Assets | $3.7M | $1.5M | $5.2M | $4.3M | $7.0M | |||
| Assets | $3.7M | $1.5M | $5.2M | $4.3M | $7.1M | |||
| Trade And Other Current Payables To Related Parties | $859.3K | $358.7K | $779.2K | $47.0K | ||||
| Adjustments For Decrease Increase Related Party Receivables | $27.4K | -$3.9K | -$543.00 | |||||
| Adjustments For Gain Loss On Disposals Property Plant And Equipment | $179.00 | $818.00 | ||||||
| Trade And Other Receivables | $242.3K | $151.9K | $592.2K | |||||
| Other Receivables | $592.2K | $813.0K | $43.4K | |||||
| Cash Advances And Loans From Related Parties | $2.0M | $496.8K | ||||||
| Increase Decrease Through Exercise Of Warrants Equity | $1.5M | |||||||
| Cash Advances And Loans Made To Related Parties | $11.2K | $132.7K | ||||||
| Rightofuse Assets | $98.6K | $30.1K | ||||||
| Loans Payable In Default | $2.2M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Increase Decrease In Cash And Cash Equivalents | $843.6K | -$3.3M | $1.6M | -$3.3M | $6.2M | -$371.4K |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -$109.5K | $63.5K | -$277.5K | -$872.1K | $445.2K | -$20.7K |
| Proceeds From Issuing Shares | 7.3M | 230.0K | 990.6K | |||
| Proceeds From Fundraising Net And Issuance Of Ordinary Shares | 1.7M | 6.2M | 7.3M | |||
| Payments Of Lease Liabilities Classified As Financing Activities | $12.3K | $6.1K | ||||
| Proceeds From Issue Of Bonds Notes And Debentures | $7.6M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Shares Issued On Total Transactions | 5.2M | 12.9M | 8.7M | 3.9M | 8.5M | 984.1K |
| Shares Issued On Options Charge | 735.0K | 1.1M | 1.3M | 1.7M | 550.1K | 36.3K |
| Diluted Earnings Loss Per Share | $-0.20 | $-0.57 | $-0.61 | $-0.36 | $-0.32 | |
| Basic Earnings Loss Per Share | $-0.20 | $-0.57 | $-0.61 | $-0.36 | $-0.32 | |
| Shares Issued Value On Expenses Settled In Shares | 32.3K | 2.4M | 86.0K | |||
| Shares Issued Value Of Fundraising Net | 1.7M | 6.2M | 7.3M | |||
| Shares Issued On Currency Translation On Convertible Loan Note Conversion | 654.8K | |||||
| Basic And Diluted Earnings Loss Per Share Attributable To Common Shareholders | $-0.01 | $-0.01 | $0.00 | |||
| Shares Issued Value Of Realted Party Loan Conversion | 3.2M | |||||
| Shares Issued On Convertible Debt Conversion | 7.6M | |||||
| Shares Issued Value Onlieu Of Interest | 750.0K | |||||
| Shares Issued Value Onlieu Of Consultancy Fees | 437.5K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Expense | $4.8M | $7.5M | $6.8M | $4.6M | $3.0M | $1.0M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -$97.0K | $55.2K | $51.2K | -$9.2K | $4.1K | $13.9K |
| Adjustments For Sharebased Payments | $735.0K | $1.1M | $1.3M | $1.7M | $550.1K | $36.3K |
| Adjustments For Depreciation Expense | $2.6K | $3.9K | $3.8K | $2.3K | $1.5K | $426.00 |
| Increase Decrease Through Exercise Of Warrants Charge | $11.4K | $29.0K | $61.7K | $83.0K | -$17.4K | |
| Increase Decrease Through Exercise Of Forfeiture | -$94.3K | -$1.4K | -$12.4K | -$19.1K | -$5.8K | |
| Adjustments For Change In Fair Value Of Warrant Charge | -$11.4K | -$29.0K | -$61.7K | -$83.0K | -$42.8K | |
| Adjustments For Change In Fair Value Of Forfeiture Of Options | $94.3K | $1.4K | $12.4K | $19.1K | $5.8K | |
| Finance Costs | $878.2K | $1.1M | $96.7K | $1.1K | $1.2K | |
| Warrant Reserve | $93.7K | $93.7K | $82.4K | $53.4K | $861.2K | |
| Share Premium | $146.7M | $143.1M | $131.4M | $124.0M | $111.6M | |
| Reserve Of Sharebased Payments | $1.2M | $4.7M | $3.6M | $2.4M | $636.3K | |
| Foreign Currency Translation Reserve | -$11.5M | -$11.3M | -$11.5M | -$11.0M | -$10.2M | |
| Expenses Settled In Shares | 32.3K | 3.5M | 86.0K | |||
| Stock Issued During Period Value New Issue | $230.0K | $965.2K | ||||
| Processed From Warrants Exercised | $2.2M | |||||
| Adjustments For Amortisation Expense | $11.6K | $5.6K | ||||
| Processed From Options Exercised | $15.9K | |||||
| Increase Decrease Through Exercise Of Options | $15.9K | |||||
| Convertible Loan Note Reserve | $950.0K | $8.4M | ||||
| Conversion Of Related Party Loan Into Shares | 3.2M |
Most recent annual filing with the SEC: July 18, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.